A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.
class Information
C173955
GDC
Anti-CD20 Monoclonal Antibody BAT4306F
802165
CL1407872
802165
802165
Anti-CD20 Monoclonal Antibody BAT4306F
Pharmacologic Substance
class Relations
- Antineoplastic Antibody
- Anti-CD20 Monoclonal Antibody
- Chemical_Or_Drug_Has_Mechanism_Of_ActionsomeAntigen Binding
- Chemical_Or_Drug_Has_Physiologic_EffectsomeAntibody-Dependent Cellular Cytotoxicity
- Chemical_Or_Drug_Affects_Cell_Type_Or_TissuesomeB-Lymphocyte
- Chemical_Or_Drug_Affects_Cell_Type_Or_TissuesomeCytotoxic T-Lymphocyte